Toward Control? The Prospects and Challenges of Typhoid Conjugate Vaccine Introduction.

With a newly World Health Organization (WHO)-prequalified typhoid conjugate vaccine (TCV), Gavi funding for eligible countries, and a WHO policy recommendation for TCV use, now is the time for countries to introduce TCVs as part of an integrated typhoid control program, particularly in light of the increasing burden of antimicrobial resistance. Continued vaccine development efforts will lead to secure supply of low-cost vaccines, and ongoing vaccine studies will provide critical vaccine performance data and inform optimal deployment strategies, in both routine use and in outbreak settings. TCV programs should include thoughtful communication planning and community engagement to counter vaccine hesitancy

Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data

Viscerotropic disease (VTD) is defined as acute multiple organ system dysfunction that occurs following vaccination. The severity of VTD ranges from relatively mild multisystem disease to severe multiple organ system failure and death. The term VTD was first used shortly after the initial published reports in 2001 of febrile multiple organ system failure following yellow fever (YF) vaccination. To date, VTD has been reported only in association with YF vaccine and has been thus referred to as YF vaccine-associated viscerotropic disease (YEL-AVD)

Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data

Submitted by Repositório Arca ([email protected]) on 2018-07-25T12:28:46Z No. of bitstreams: 2 license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5) Bio-0013.pdf: 852994 bytes, checksum: d75cd666d8542005d0e6016ba864dbf2 (MD5)Approved for entry into archive by Priscila Nascimento ([email protected]) on 2018-10-04T20:06:06Z (GMT) No. of bitstreams: 2 Bio-0013.pdf: 852994 bytes, checksum: d75cd666d8542005d0e6016ba864dbf2 (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5)Made available in DSpace on 2018-10-04T20:06:06Z (GMT). No. of bitstreams: 2 Bio-0013.pdf: 852994 bytes, checksum: d75cd666d8542005d0e6016ba864dbf2 (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5) Previous issue date: 2012Centers for Disease Control and Prevention. Division of Global Migration and Quarantine. National Center for Emerging and Zoonotic Infectious Diseases. Atlanta, GA, USA. / Centers for Disease Control and Prevention. Division of Vector-Borne Diseases. National Center for Emerging and Zoonotic Infectious Diseases. Fort Collins, CO, USA.World Health Organization. Department of Immunization, Vaccines, and Biologicals. Geneva, Switzerland.Institut Pasteur. Agence de Médecine Préventive. Paris, France.Hospital das Clinicas. Division of Clinical Immunology and Allergy. São Paulo, SP, Brasil.Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública. Rio de Janeiro, Brasil.Sanofipasteur. Global Pharmacovigilance & Epidemiology. Lyon, France. Robert Koch Institute. Berlin, Germany. / Sanofipasteur. Division of Safety Monitoring and Risk Management for Pediatric and Travel Vaccines. Lyon, France.Department of International Health. Center for Immunization Research. Johns Hopkins Bloomberg School of Public Health. Baltimore, MD, USA.Barcelona Centre for International Health Research. Barcelona, Espanha.National Centre of Epidemiology. International Traveller’s Health and Vaccination Centre. Budapest, Hungary.Sanofipasteur. Global Pharmacovigilance and Epidemiology Department. Toronto, Canada.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Ministry of Health. Epidemiology Direction. Buenos Aires Province, Argentina.Rouen University Hospital. Pharmacovigilance Regional Center of Upper-Normandy. Rouen, Cedex, France.Federal Ministry of Health. Federal Secretariat. Maitama, Abuja, Nigeria.National Institutes of Health. National Institute of Allergy and Infectious Diseases. Division of AIDS. Bethesda, USA.Novartis Vaccines. Cambridge, USA.Harvard School of Public Health. Department of Global Health and Population. Boston, USA

Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data

Viscerotropic disease (VTD) is defined as acute multiple organ system dysfunction that occurs following vaccination. The severity of VTD ranges from relatively mild multisystem disease to severe multiple organ system failure and death. The term VTD was first used shortly after the initial published reports in 2001 of febrile multiple organ system failure following yellow fever (YF) vaccination. To date, VTD has been reported only in association with YF vaccine and has been thus referred to as YF vaccine-associated viscerotropic disease (YEL-AVD)